-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Arbidol Included in the COVID-19 Diagnosis and Treatment Protocol (Sixth Edition); Shijiazhuang No.4 Pharmaceutical Accelerates Production to Ensure Supply
Category:
发布时间：2020-02-20
【概要描述】
On the afternoon of February 19, the General Office of the National Health Commission and the Office of the State Administration of Traditional Chinese Medicine jointly issued the “Notice on the Issuance of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6).”
On the afternoon of February 19, the General Office of the National Health Commission and the Office of the State Administration of Traditional Chinese Medicine jointly issued the “Notice on the Issuance of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6).” This updated protocol adds chloroquine phosphate and arbidol as antiviral treatments. As soon as the news broke, call centers across the country were inundated with inquiries about additional supplies of arbidol hydrochloride capsules manufactured by Shijiazhuang No. 4 Pharmaceutical Co., Ltd. Currently, Shijiazhuang No. 4 Pharmaceutical is ramping up production to ensure a stable supply.
Since the outbreak of the epidemic, the oral dosage-form workshop at Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been operating at full capacity on its abidor hydrochloride capsule production line. “At present, regions across the country are continuously increasing their procurement orders for abidor hydrochloride capsules. To meet this demand, we have maintained round-the-clock production with all staff working without days off, producing nearly 1 million capsules per day—almost double our usual output—in an effort to ensure adequate supply for clinical use and the market,” said Han Shuqin, the company’s deputy general manager in charge of manufacturing, on February 19.
According to available information, from January 25 to February 18, Shisi Pharmaceutical has cumulatively shipped 1.5 million capsules of the antiviral drug arbidol hydrochloride to Hubei Province, including 1.1 million capsules destined for Wuhan.
Shi Si Yao is one of the earliest pharmaceutical companies in China to develop the drug arbidol. According to Dr. Sun Lijie, Director of the Shi Si Yao Pharmaceutical Research Institute, arbidol is primarily used to treat upper respiratory tract infections caused by influenza A and B viruses, among others. In 2019, it was first included in the National Medical Insurance Catalogue and has since been repeatedly listed as a clinically recommended antiviral agent for influenza in the guidelines issued by the National Health Commission.
Sun Lijie stated that the inclusion of arbidol in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6) has further strengthened our resolve to accelerate further research on this drug, thereby enabling it to better realize its clinical value.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091